In recent years, high-throughput sequencing technologies have led to the identification of many driver and passenger alterations that enable precision medicine (e.g. IDH1 inhibitor ivosidenib in AML patients) (2, 5–9). Here, IDH1 is linked to acute myeloid leukemia.